Intracellular Th Stock Performance
| ITCI Stock | USD 126.20 0.06 0.05% |
On a scale of 0 to 100, Intracellular holds a performance score of 14. The company retains a Market Volatility (i.e., Beta) of -0.0411, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Intracellular are expected to decrease at a much lower rate. During the bear market, Intracellular is likely to outperform the market. Please check Intracellular's expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether Intracellular's current trending patterns will revert.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Intracellular Th are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite fairly uncertain fundamental indicators, Intracellular demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 150.4 M |
Intracellular |
Intracellular Relative Risk vs. Return Landscape
If you would invest 7,691 in Intracellular Th on October 20, 2024 and sell it today you would earn a total of 4,929 from holding Intracellular Th or generate 64.09% return on investment over 90 days. Intracellular Th is currently generating 0.927% in daily expected returns and assumes 5.1498% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Intracellular, and 82% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Intracellular Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intracellular's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Intracellular Th, and traders can use it to determine the average amount a Intracellular's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.18
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ITCI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.15 actual daily | 45 55% of assets are more volatile |
Expected Return
| 0.93 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Intracellular is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Intracellular by adding it to a well-diversified portfolio.
Intracellular Fundamentals Growth
Intracellular Stock prices reflect investors' perceptions of the future prospects and financial health of Intracellular, and Intracellular fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Intracellular Stock performance.
| Return On Equity | -0.099 | ||||
| Return On Asset | -0.0745 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | 12.47 B | ||||
| Shares Outstanding | 106.24 M | ||||
| Price To Earning | (6.56) X | ||||
| Price To Book | 11.76 X | ||||
| Price To Sales | 21.86 X | ||||
| Revenue | 464.37 M | ||||
| EBITDA | (158.85 M) | ||||
| Cash And Equivalents | 628.74 M | ||||
| Cash Per Share | 6.64 X | ||||
| Total Debt | 16.94 M | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 10.80 X | ||||
| Cash Flow From Operations | (124.2 M) | ||||
| Earnings Per Share | (0.87) X | ||||
| Total Asset | 728.29 M | ||||
| Retained Earnings | (1.62 B) | ||||
| Current Asset | 541.82 M | ||||
| Current Liabilities | 140.69 M | ||||
About Intracellular Performance
By evaluating Intracellular's fundamental ratios, stakeholders can gain valuable insights into Intracellular's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Intracellular has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Intracellular has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.Things to note about Intracellular Th performance evaluation
Checking the ongoing alerts about Intracellular for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Intracellular Th help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Intracellular Th is way too risky over 90 days horizon | |
| Intracellular Th appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 464.37 M. Net Loss for the year was (139.67 M) with profit before overhead, payroll, taxes, and interest of 349.86 M. | |
| Intracellular Th currently holds about 628.74 M in cash with (124.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.64. | |
| Intracellular Th has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are owned by institutional investors |
- Analyzing Intracellular's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Intracellular's stock is overvalued or undervalued compared to its peers.
- Examining Intracellular's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Intracellular's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Intracellular's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Intracellular's stock. These opinions can provide insight into Intracellular's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |